Zhenya Lindgardt Sells 38,899 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 38,899 shares of the stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total value of $364,483.63. Following the transaction, the chief executive officer now directly owns 908,104 shares in the company, valued at approximately $8,508,934.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, February 6th, Zhenya Lindgardt sold 27,997 shares of Sera Prognostics stock. The shares were sold at an average price of $8.03, for a total value of $224,815.91.

Sera Prognostics Stock Down 0.4 %

SERA opened at $9.46 on Thursday. The stock’s 50 day moving average price is $8.40 and its two-hundred day moving average price is $5.00. Sera Prognostics, Inc. has a 12-month low of $1.52 and a 12-month high of $10.44.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Captrust Financial Advisors acquired a new stake in Sera Prognostics in the 3rd quarter valued at approximately $381,000. Price T Rowe Associates Inc. MD acquired a new stake in Sera Prognostics in the 4th quarter valued at approximately $909,000. Vanguard Group Inc. lifted its position in shares of Sera Prognostics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 909,502 shares of the company’s stock worth $5,439,000 after acquiring an additional 122,710 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Sera Prognostics in the 2nd quarter worth approximately $179,000. Finally, Perigon Wealth Management LLC bought a new stake in shares of Sera Prognostics in the 4th quarter worth approximately $509,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.